Orgenesis Inc. (ORGS)
USD 2.4
(10.6%)
USD 2.4
(10.6%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -55.36 Million USD | -354.93% |
| 2022 | -12.16 Million USD | 32.62% |
| 2021 | -18.05 Million USD | 81.02% |
| 2020 | -95.12 Million USD | -265.3% |
| 2019 | -26.04 Million USD | -42.37% |
| 2018 | -18.29 Million USD | -47.9% |
| 2017 | -12.36 Million USD | -34.51% |
| 2016 | -9.19 Million USD | -106.1% |
| 2015 | -4.46 Million USD | 18.95% |
| 2014 | -5.5 Million USD | 0.63% |
| 2013 | -5.53 Million USD | -10.82% |
| 2012 | -4.99 Million USD | -6808.09% |
| 2011 | -72.35 Thousand USD | -100.02% |
| 2010 | -36.17 Thousand USD | -41.04% |
| 2009 | -25.64 Thousand USD | -632.8% |
| 2008 | -3500.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -9.76 Million USD | 71.61% |
| 2024 Q2 | -8.9 Million USD | 8.82% |
| 2023 Q3 | 12.65 Million USD | 406.59% |
| 2023 Q1 | -4.26 Million USD | -234.98% |
| 2023 FY | -55.36 Million USD | -354.93% |
| 2023 Q2 | -4.12 Million USD | 3.14% |
| 2023 Q4 | -34.39 Million USD | -371.81% |
| 2022 Q1 | -3.99 Million USD | 20.31% |
| 2022 FY | -12.16 Million USD | 32.62% |
| 2022 Q4 | -1.27 Million USD | 9.66% |
| 2022 Q3 | -1.4 Million USD | 74.36% |
| 2022 Q2 | -5.49 Million USD | -37.4% |
| 2021 Q4 | -5.01 Million USD | 50.63% |
| 2021 Q1 | -219 Thousand USD | 99.58% |
| 2021 FY | -18.05 Million USD | 81.02% |
| 2021 Q3 | -10.15 Million USD | -282.06% |
| 2021 Q2 | -2.65 Million USD | -1114.16% |
| 2020 Q2 | -20.4 Million USD | -127.01% |
| 2020 Q1 | 75.55 Million USD | 1346.78% |
| 2020 Q3 | -2.42 Million USD | 88.11% |
| 2020 Q4 | -51.61 Million USD | -2026.58% |
| 2020 FY | -95.12 Million USD | -265.3% |
| 2019 Q3 | -4.54 Million USD | 12.54% |
| 2019 Q1 | -8.31 Million USD | -66.35% |
| 2019 Q2 | -5.2 Million USD | 37.42% |
| 2019 FY | -26.04 Million USD | -42.37% |
| 2019 Q4 | -6.06 Million USD | -33.22% |
| 2018 Q2 | -2.61 Million USD | 53.41% |
| 2018 FY | -18.29 Million USD | -47.9% |
| 2018 Q3 | -5.07 Million USD | -93.96% |
| 2018 Q4 | -4.99 Million USD | 1.46% |
| 2018 Q1 | -5.61 Million USD | -555.49% |
| 2017 Q3 | -1.95 Million USD | -249.37% |
| 2017 Q4 | -856 Thousand USD | 56.17% |
| 2017 FY | -12.36 Million USD | -34.51% |
| 2017 Q2 | -559 Thousand USD | 93.79% |
| 2017 Q1 | -8.99 Million USD | -212.25% |
| 2016 FY | -9.19 Million USD | -106.1% |
| 2016 Q4 | -2.88 Million USD | -9.0% |
| 2016 Q3 | -2.64 Million USD | 32.07% |
| 2016 Q2 | -3.89 Million USD | -1829.78% |
| 2016 Q1 | 225 Thousand USD | 123.48% |
| 2015 Q2 | -1.09 Million USD | -38.8% |
| 2015 Q3 | -1.61 Million USD | -47.29% |
| 2015 FY | -4.46 Million USD | 18.95% |
| 2015 Q4 | -958.41 Thousand USD | 40.68% |
| 2015 Q1 | -790.21 Thousand USD | -260.13% |
| 2014 Q1 | -709.31 Thousand USD | 58.65% |
| 2014 Q4 | 493.46 Thousand USD | 114.13% |
| 2014 FY | -5.5 Million USD | 0.63% |
| 2014 Q3 | -3.49 Million USD | -94.44% |
| 2014 Q2 | -1.79 Million USD | -153.2% |
| 2013 Q3 | -937.44 Thousand USD | 39.78% |
| 2013 Q1 | -1.32 Million USD | 4.62% |
| 2013 FY | -5.53 Million USD | -10.82% |
| 2013 Q4 | -1.71 Million USD | -82.97% |
| 2013 Q2 | -1.55 Million USD | -17.06% |
| 2012 FY | -4.99 Million USD | -6808.09% |
| 2012 Q4 | -1.39 Million USD | 25.65% |
| 2012 Q3 | -1.87 Million USD | -114.36% |
| 2012 Q2 | -874.81 Thousand USD | -2.45% |
| 2012 Q1 | -853.86 Thousand USD | -1279.06% |
| 2011 Q1 | -5436.00 USD | 76.36% |
| 2011 FY | -72.35 Thousand USD | -100.02% |
| 2011 Q4 | -61.91 Thousand USD | -2163.84% |
| 2011 Q3 | -2735.00 USD | -20.75% |
| 2011 Q2 | -2265.00 USD | 58.33% |
| 2010 Q4 | -22.99 Thousand USD | -317.13% |
| 2010 Q3 | -5512.00 USD | -12.72% |
| 2010 FY | -36.17 Thousand USD | -41.04% |
| 2010 Q2 | -4890.00 USD | -75.96% |
| 2010 Q1 | -2779.00 USD | 45.14% |
| 2009 Q1 | -1706.00 USD | 0.0% |
| 2009 Q4 | -5066.00 USD | 62.16% |
| 2009 Q3 | -13.38 Thousand USD | -144.06% |
| 2009 FY | -25.64 Thousand USD | -632.8% |
| 2009 Q2 | -5486.00 USD | -221.57% |
| 2008 FY | -3500.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -7170.757% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -541.346% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | -80.042% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 55.395% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | -244.328% |
| Better Therapeutics, Inc. | -39.76 Million USD | -39.238% |
| Calithera Biosciences, Inc. | -18.86 Million USD | -193.443% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | -201.236% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | -54.592% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | -53.503% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 51.661% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | -2362.393% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 25.942% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 6.298% |
| Innovation1 Biotech Inc. | -5.98 Million USD | -824.491% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | -159.984% |
| Molecular Templates, Inc. | -8.12 Million USD | -581.45% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -264.765% |
| NexImmune, Inc. | -32.34 Million USD | -71.161% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | -119.139% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -70860.175% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | -202.689% |
| Scopus BioPharma Inc. | -11.6 Million USD | -376.846% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 90.336% |
| Statera Biopharma, Inc. | -174.4 Million USD | 68.258% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -1442.949% |
| Trevena, Inc. | -40.28 Million USD | -37.41% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -97137.152% |
| Vaccinex, Inc. | -20.25 Million USD | -173.374% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -4583.228% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | -8.428% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -611.839% |